Máj- és epeúti rák: ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• PD-1 92
• PD-L1 51
• TP53 3
• PI3K 0
• mTOR 1
• AKT 0
• STAT3 1
• VEGF 20
• FGFR 22
• GPC3 38
• CTNNB1 5
• YAP 0
• HER2 28
• MAPK 0
• NRF2 0
• HIF-1 0
• PPAR 0
• ERK 0
• AMPK 0
• EGFR 8
• STING 0
• CTLA-4 20
• MYC 0
• IDH 6
• JAK 0
• JNK 0
• PTEN 0
• GPX4 0
• KRAS 8
• BCL-2 0
• HSP90 0
• IL-6 1
• PSMA 8
• MET 1
• GLP-1 1
• BRAF 3
• EZH2 0
• NLRP3 0
• CLDN18 10
• MEK 0
• B7-H3 5
• COX-2 0
• HDAC 0
• CXCR4 0
• HMGB1 0
• METTL3 0
• SIRT1 0
• TLR4 0
• MMP-9 0
• TNF 0
• PARP 2
• PCSK9 0
• TIGIT 2
• TIM-3 1
• CDK4/6 0
• IL-17 0
• RAS 2
• SGLT2 0
• CD47 0
• IL-15 2

54+ intézményből 24, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NCI · R44

  Overcoming Immune Evasion in Hepatocellular Carcinoma with Engineered T-Cell Therapy

  March Biosciences Inc· Houston, Egyesült Államok· 399 003 USD awarded in fiscal year 2026· until 2027. aug.

• NIH NIDDK · R01

  Stakeholder Engagement and Modeling for Adoption of a Novel Cirrhosis Detection Algorithm

  University of Michigan at Ann Arbor· Ann Arbor, Egyesült Államok· 810 994 USD awarded in fiscal year 2026· until 2030. jún.

• NIH NCI · R01

  Assessment of sound waves from liver vessels via artificial intelligence to detect liver cancer

  University of Minnesota· Minneapolis, Egyesült Államok· 18 735 USD awarded in fiscal year 2026· until 2031. aug.

• NIH NCI · R41

  MUSIC: Multiplexed siRNA and CRISPR in an LNP to knockout cancer

  Jumble Therapeutics, Inc· Cambridge, Egyesült Államok· 395 652 USD awarded in fiscal year 2026· until 2027. aug.

• NIH NCI · K08

  Metabolic Imaging to Enable Targeted Therapy for Hepatocellular Carcinoma

  University of Pennsylvania· Philadelphia, Egyesült Államok· 296 232 USD awarded in fiscal year 2026· until 2031. aug.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Glutaminase Isoenzymes: Gatekeepers of Bioenergetics, Immunity, and Tumor Microenvironment in Diabetes-Induced Hepatocellular Carcinoma (IRM)

  Fundacion Para la Investigacion de Malaga En Biomedicina y Salud· Malaga, Spanyolország· EU contribution 209 915 EUR· until 2029. aug.

• European Commission (Horizon Europe) · HORIZON-ERC

  Decoding Neural Circuits in Cholangiocarcinoma (LIVER-CIRCUITS)

  Technische Universitaet Dresden· Dresden, Németország· EU contribution 1 500 000 EUR· until 2031. dec.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Unravelling Malignant Cholangiocyte Subpopulations that Drive Chemoresistance in Cholangiocarcinoma (RESIST-CCA)

  Humanitas Mirasole Spa· Rozzano (Mi), Olaszország· EU contribution 193 643 EUR· until 2028. dec.

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Multiscale 3D virtual histology with non-destructive x-rays (XHIST)

  Danmarks Tekniske Universitet· Kongens Lyngby, Dánia· EU contribution 150 000 EUR· until 2028. márc.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Mechano-metabOlic Responsive nanoPlatform for HeterogEnous tUmor Suppression (MORPHEUS)

  Fundacion de la Comunidad Valenciana Centro de Investigacion Principe Felipe· Valencia, Spanyolország· EU contribution 2 499 745 EUR· until 2031. aug.

  The disease is named only in the funder's project summary, not in the title.

10 of 875 running projects, newest first. Listed amounts together: 477,7 M USD + 133,0 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Leállított, visszavont és felfüggesztett vizsgálatok, a szponzor által a regiszterben megadott okkal, szó szerint idézve.

• Leállították

  A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors

  NCT04278144· Bolt Biotherapeutics, Inc.· Frissítve: 2025. szept. 15.

  “Sponsor Decision”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  A Trial of SHR1258 in Patients With Biliary Tract Cancer

  NCT04571710· Jiangsu HengRui Medicine Co., Ltd.· Frissítve: 2025. júl. 24.

  “The sponsor's R\&D strategy is adjusted.”A regiszter szövege, változtatás nélkül. Forrás

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

  NCT06282575· Jazz Pharmaceuticals· Forrás

• A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)

  NCT06330064· Daiichi Sankyo· Forrás

• Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer

  NCT06467357· AstraZeneca· Forrás

• DESTINY-PANTUMOUR04

  NCT07124000· AstraZeneca· Forrás

• Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor

  NCT05523947· Yuhan Corporation· Forrás

• ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors

  NCT06973161· AstraZeneca· Forrás

• A COMPREHENSIVE BIOMARKER EVALUATION IN BILIARY TRACT CANCER

  NCT07515950· MedSIR· Forrás

• Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers

  NCT04430738· Seagen, a wholly owned subsidiary of Pfizer· Forrás

• A Study of ZW25 (Zanidatamab) in Subjects With Advanced or Metastatic HER2-Amplified Biliary Tract Cancers

  NCT04466891· Jazz Pharmaceuticals· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 109
• Organoids 40
• Mendelian Randomization Analysis 38
• CRISPR-Cas Systems 34
• Gene Expression Profiling 281
• Sequence Analysis, RNA 20
• Whole Genome Sequencing 9
• Exome Sequencing 19
• Proteomics 119
• Metabolomics 73
• Mass Spectrometry 23
• Flow Cytometry 66
• Immunohistochemistry 125
• Liquid Biopsy 34
• Circulating Tumor DNA 42
• Xenograft Model Antitumor Assays 443
• Positron-Emission Tomography 35
• Magnetic Resonance Imaging 376
• Machine Learning 199
• Deep Learning 114
• Cohort Studies 184
• Genome-Wide Association Study 42

• Therapeutic and Predicted Significance of PKLR in Patients With Cholangiocarcinoma.

  Cancer Rep (Hoboken), 2026. aug.

• Geographic and genetic diversity in gallbladder cancer mutation profiles: insights from a worldwide exome analysis.

  EBioMedicine, 2026. máj.

• Targeting a tolerogenic HLA-G genotype to tackle immune evasion and adaptive resistance in HBV-driven HCC.

  JHEP Rep, 2026. máj.

• Whole-Exome Sequencing Identifies Frequent AHNAK2 Mutations With Prognostic Significance in Undifferentiated Primary Liver Carcinoma.

  Am J Surg Pathol, 2026. ápr.

• Single-cell analysis reveals a LAMB3-dependent immunosuppressive environment in gallbladder neck/cystic duct carcinoma.

  JHEP Rep, 2026. ápr.

• Recurrent Resistance Mutations to Lirafugratinib Inform Treatment Sequencing in FGFR2-Driven Tumors.

  Clin Cancer Res, 2026. ápr.

• Chemoresistance and genetic mutations in hepatocellular carcinoma: a pharmacogenomic atlas of 51 patients.

  BMC Cancer, 2026. márc.

• Single-cell transcriptomic mapping of patient-derived primary liver cancer organoids reveals molecular subtypes and guides precision drug targeting.

  Cell Oncol (Dordr), 2026. márc.

• Multi-omics profiling reveals divergent biology and liver microenvironment in HCC of metastatic and de novo origin.

  Mol Cancer, 2026. márc.

• ERBB2 I655V mutation correlates with efficacy of immunotherapy in gallbladder cancer.

  World J Surg Oncol, 2026. febr.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.